Wall Street brokerages expect Evoke Pharma Inc (NASDAQ:EVOK) to announce earnings of ($0.17) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evoke Pharma’s earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.14). Evoke Pharma reported earnings per share of ($0.14) during the same quarter last year, which indicates a negative year over year growth rate of 21.4%. The company is expected to announce its next earnings results on Monday, May 21st.
According to Zacks, analysts expect that Evoke Pharma will report full year earnings of $0.11 per share for the current fiscal year, with EPS estimates ranging from ($0.42) to $1.16. For the next year, analysts anticipate that the business will report earnings of $0.23 per share, with EPS estimates ranging from ($0.83) to $1.85. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.21.
Several research analysts recently commented on EVOK shares. Zacks Investment Research upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Evoke Pharma in a report on Tuesday, March 6th. Finally, B. Riley restated a “buy” rating and set a $5.00 price objective (down previously from $10.00) on shares of Evoke Pharma in a report on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $7.71.
Several large investors have recently bought and sold shares of EVOK. Creative Planning bought a new position in shares of Evoke Pharma during the 4th quarter worth about $226,000. B. Riley Financial Inc. bought a new position in shares of Evoke Pharma during the 4th quarter worth about $249,000. 683 Capital Management LLC bought a new position in shares of Evoke Pharma during the 4th quarter worth about $258,000. Deutsche Bank AG bought a new position in shares of Evoke Pharma during the 4th quarter worth about $452,000. Finally, Vanguard Group Inc. increased its holdings in shares of Evoke Pharma by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the period. Institutional investors own 18.42% of the company’s stock.
Shares of EVOK opened at $2.14 on Friday. The firm has a market capitalization of $33.16, a P/E ratio of -2.58 and a beta of 1.38. Evoke Pharma has a one year low of $1.85 and a one year high of $4.09.
ILLEGAL ACTIVITY NOTICE: This report was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/16/zacks-brokerages-expect-evoke-pharma-inc-evok-to-announce-0-17-eps.html.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.